Q-omics provides the consensus-scored ABHD8 profile across patient tissues and cancer cell-line models. ABHD8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ABHD8 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, ABHD8 RNA expression shows 18,353 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where ABHD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD8 survival associations across molecular data types. ABHD8 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD8 RNA expression–survival associations across cancer types. High ABHD8 expression shows unfavorable associations in KICH and LIHC, but favorable associations in UVM, SCLC, PAAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ABHD8 RNA expression.
This table summarizes ABHD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ABHD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD8 shows lower tumor expression in COAD and LUAD and higher tumor expression in KIRP, LIHC, HNSC and BRCA. The KIRP box plot shows higher ABHD8 RNA expression in tumor versus normal tissue (log2 FC = +0.772, t-test p < 0.001).
This table shows molecular features associated with ABHD8 in patient tissues and cancer cell lines. In patient samples, ABHD8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
